News

6 December 2024
Major Australian breakthrough could revolutionise hypertension treatment.
27 November, 2024 MELBOURNE, Australia — In a significant international breakthrough for the more than one billion people suffering from hypertension, Australian-supported research recently published in three of the world’s leading medical journals – The Lancet, the Journal of the American Medical Association (JAMA) and the Journal of the American College of Cardiology (JACC) – […]
10 September 2024
Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
10 September 2024 London UK, 10 September 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the appointment of accomplished biotech executive, Enoch Kariuki, Pharm.D., to its Board of Directors as an independent, non-executive director. Dr. Kariuki possesses extensive strategic, operational, […]
13 May 2024
Respirion offers hope for people living with cystic fibrosis
A promising new treatment pioneered in Western Australia for people with cystic fibrosis has commenced testing in a clinical trial in the United States and Australia. Developed by researchers at Telethon Kids Institute and Perth Children’s Hospital, the treatment, known as RSP-1502, uses an antibiotic booster to improve the effectiveness of treatment for respiratory infections […]
2 April 2024
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
— Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) and the Association for Research in Vision and Ophthalmology (ARVO), showcasing a breadth of data supporting the potential for a new therapeutic class to treat underserved ophthalmic conditions— — New and updated data show investigational AZR-MD-001 demonstrates durability of […]
6 December 2023
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland. The data highlight that treatment with a combination of CatalYm’s lead candidate visugromab and […]
27 November 2023
Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies  
Scientists Uncover Central Role of N-Myristoylation in Senescence London, UK, 27 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase (NMT) inhibition, is pleased to announce the publication today of ground-breaking research in Nature Cell Biology1 by its collaborators at […]
26 November 2023
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
CAMBRIDGE, Mass. & BRISBANE, Australia-Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch, instead of using traditional needle and syringe. “The HD-MAPs thermostability qualities and potential to […]
16 November 2023
Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma
Melbourne, Australia: 16 November 2023 – Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, announces the presentation of results of its Phase 2 clinical trial of FT011 in patients with scleroderma at ACR Convergence 2023, the annual scientific meeting of the American College of Rheumatology being held […]
15 November 2023
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
London, UK 15 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company […]
2 November 2023
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery,biodegradable ocular implant in glaucoma patients.
Melbourne, 1st November 2023: PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform. Today the company reported promising interim results from an ongoing Phase 2a clinical study for its PA5108 Ocular Implant in subjects with mild to moderate glaucoma. This ocular implant is designed to deliver 6 months of latanoprost and […]
19 October 2023
Myricx Bio Wins Best Poster at World ADC
London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the award for Best Poster at the 14th Annual #WorldADC conference, San Diego, California, held from October 16-19, 20231. The […]
9 October 2023
 Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease
Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease Melbourne, Australia and London UK, 10 October 2023 – Brandon Capital, an international venture capital firm and Australasia’s leading early-stage life science investor, is pleased to announce its investment into AstronauTx Ltd, a UK-based biotech company developing […]
27 September 2023
Recruitment completes for second Phase III hypertension trial investigating GMRx2
George Medicines completes recruitment of second Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 – More than 250 patients enrolled in placebo-controlled trial evaluating efficacy and safety of GMRx2 as treatment for hypertension including first line therapy– Novel, patent-protected low and ultra-low dose triple combinations of best-in-class treatments which are designed for […]
27 September 2023
Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer
Company Collaborating with Researchers at the University of Nottingham on Optimization and Evaluation of Novel Small Molecule GPR65 Inhibitors in Preclinical Brain Tumor Models OXFORD, UK – September 27, 2023 Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced that the company has been awarded a […]
11 September 2023
New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of complications associated with respiratory viral infections. As previously reported, data from post-hoc analyses excluding those with pre-existing immunity against […]
5 September 2023
Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
BOSTON-Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, including obesity and type 2 diabetes, with first-in-class oral polymer medicines that address unmet needs for patients globally, today announced the appointment of Sapan Shah, Ph.D., as Chief Executive Officer. Dr. Shah has more than 25 years of experience leading innovative […]
27 August 2023
Dr. Yuri Maricich joins PKG Health as its Chief Medical & Scientific Officer
PKG Health is pleased to announce that Dr. Yuri Maricich has joined the leadership team as Chief Medical & Scientific Officer. Dr. Maricich is a licensed physician-scientist, therapeutic developer, investor, and strategist.  He brings a unique blend of medical practice, biotech, and digital health experience and expertise.  Dr. Maricich has a history of improving our […]
23 August 2023
VAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH
Cambridge, Mass., USA, and Brisbane, Queensland, Australia – August 23, 2023 – Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million (AU$5.4 million / GB£2.84 million) to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation […]
15 August 2023
CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Expressions of Interest for CUREator+, a newly created $50 million program by Brandon BioCatalyst and ANDHealth, are now open. Selected by the Federal Government’s Medical Research Future Fund (MRFF) through a competitive process, Brandon BioCatalyst in partnership with ANDHealth will deliver the incubator program to startup companies with commercial potential. CUREator+ will provide successful startup […]
18 July 2023
State Government Backs OncoRes Medical with Funding to Manufacture Digital Cancer ImagingDevice in WA
Perth, 18/07/2023 – OncoRes Medical, a Perth-based medical device company, has secured $3M grant funding from the Cook Government’s Department of Jobs, Tourism, Science, and Innovation, further bolstering their successful financial year. The funding brings the total to $22M raised, $10.5M in a Series A2 raise in 2022 matched with $11.5M in State and Federal […]
6 June 2023
Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology. The COVID-19 vaccine patch is based upon HD-MAP delivery of a SARS-CoV-2 spike subunit vaccine candidate from The […]
6 June 2023
Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technology, today announced the appointment of Dr. Rochelle Chaiken, as Chief Medical Officer. Dr. Chaiken joins Vaxxas following a 23-year career at Pfizer, bringing extensive experience designing and executing late-stage clinical trials and successfully launching new products in markets. Reporting to Vaxxas Chief Executive Officer […]
2 June 2023
Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity. Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers […]
2 June 2023
Aravax doses first patient in Phase 2 peanut allergy clinical trials
The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U.S. FDA Investigational New Drug Application. Allergy clinical trial centres across Victoria, South Australia, […]
22 May 2023
EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation
Melbourne, 22 May 2023 – EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System. EBR Systems’ WiSE CRT System is on track for the Premarket Approval (PMA) application to […]
10 March 2023
Aravax initiates Phase 2 peanut allergy clinical trials in Australia
Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are safe, convenient, and precisely targeted, today announces it has initiated the first clinical trial sites in Australia for AVX-201 in Australia, a Phase 2 trial of PVX108 for the treatment of peanut allergy. Aravax received the green light for its Investigational New Drug […]
10 February 2023
Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary needle-free vaccine technology, the high-density microarray patch (HD-MAP). The Phase I clinical trial will assess the safety, tolerability, and immunogenicity of […]
6 February 2023
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Data from Certa Therapeutics’ Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key composite endpoint for systemic sclerosis) lung function, SHAQ-DI and Physician Global Assessment; The trial results also […]
20 December 2022
Billionaires Andrew and Nicola Forrest take aim at peanut allergy
Billionaires Andrew and Nicola Forrest are taking aim at peanut allergy with their new healthcare venture, backing a small biotech looking to develop the first safe, convenient, and targeted treatment for the common allergen. Tenmile was launched with an initial $250 million investment in August and is owned by Tattarang, the Forrest family office. After […]
6 December 2022
Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) molecules Founding team comprised of world-class scientific leaders Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has raised […]
6 December 2022
Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate
Vaxxas to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities toward commercial scale. Equity funding to leverage non-dilutive financial support of more than US$67 million (A$100 million) which has been provided and committed under contracts with US and Australian government agencies, industry collaborators, and global health organizations. Investment round led by […]
22 November 2022
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the continued, promising clinical development […]
17 November 2022
Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction Restoration of gland function shown to improve downstream response measures of ocular conditions associated with Meibomian Gland Dysfunction Rapidly advancing AZR-MD-001 to Phase 3 in 2023 – Azura Ophthalmics Ltd., […]
11 November 2022
QUE Oncology’s non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet
QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor symptoms (commonly known as hot flashes/flushes and night sweats) in women taking endocrine therapy for breast cancer, have been published in The Lancet. Around 75 per cent of breast cancers are hormone-sensitive, with […]
9 November 2022
Brandon Capital Invests in Neuroscience Company NRG Therapeutics
Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds NRG is developing inhibitors of a first-in-class target as a potential disease-modifying treatment for Parkinson’s and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) towards the clinic The financing enables UK-headquartered NRG Therapeutics to expand its […]
9 November 2022
First Aussies to get needle-free COVID-19 vaccine patch
Brisbane-based vaccine technology company Vaxxas has kicked off its first human clinical trial of its needle-free patches to combat COVID-19. The phase one trial is taking place at the University of the Sunshine Coast’s Sippy Downs clinical research location and will involve 44 Australians aged 18 to 50, each of whom have had three doses […]
9 November 2022
Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology. The Phase I Clinical Study is being conducted in Australia at the University of the Sunshine Coast’s Sippy Downs […]
4 November 2022
Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
Findings to showcase the promise of company’s ‘Macrophage Conditioning’ approach in reversing immunosuppression within acidic tumor microenvironment and driving anti-tumor activity Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced that new preclinical data highlighting the therapeutic potential of the company’s novel GPR65 inhibition platform will […]
2 November 2022
First in-human use of OncoRes Medical’s cancer imaging technology successful
Quantitative Micro-Elastography (QME) Imaging System published in peer reviewed Cancer Research Perth, 02 November 2022: OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System.  The study, titled Quantitative micro-elastography enables in vivo detection of residual cancer in the surgical cavity during breast-conserving surgery was published in […]
20 October 2022
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Supports continued advancement of first-in-class Ophthalmic Keratolytics for ocular surface diseases Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was granted by the U.S. Patent and Trademark Office. This patent strengthens the company’s extensive […]
28 September 2022
Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Financing led by Brandon Capital from its newly established UK operation; Forbion and Atlas Venture co-led the round USD68M series A will enable London-based Pheon Therapeutics to advance its lead ADC compound targeting a novel cancer antigen and further develop its proprietary payload platform for development of novel ADCs Jonathan Tobin, Partner at Brandon Capital […]
21 September 2022
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
SAB comprised of leading experts in ophthalmology to provide strategic support for the advancement of Azura’s first-in-class Ophthalmic Keratolytics Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the formation of its scientific advisory board (SAB), comprised of leading academic and industry innovators. […]
21 September 2022
Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
GLY-200 is a First-in-Class, Oral, Gut-Targeted Approach for Treatment of Type 2 Diabetes and Related Metabolic Conditions Newly Released Phase 1 Biomarker Data is Consistent with Effects of Roux-en-Y Gastric Bypass Surgery and Duodenal Exclusion Devices Initial Data from Phase 2 Trial Evaluating GLY-200 in Patients with Type 2 Diabetes Anticipated in Early 2023 Glyscend […]
8 September 2022
George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage development with global Phase III trials underway Single-pill triple combination outperformed standard treatments without additional adverse effects in earlier clinical research VERONICA-Nigeria trial aims for more than 80% blood pressure control while improving cost-effectiveness in treating hypertension, providing a potential valuable tool to address the […]
5 September 2022
$16m cash injection to progress first-in-class therapy for inflammation and fibrosis
Australian start-up OccuRx accelerates therapy development for diseases associated with inflammation and fibrosis – the cause of 45% of all deaths globally1 Australian biotech start-up OccuRx today announces a $16m cash injection to progress into clinical phase studies for its oral therapy for inflammation and fibrosis – one of the leading causes of deaths globally[1]. […]
28 August 2022
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study protocol of AZR-MD-001 in Meibomian Gland Dysfunction (MGD). AZR-MD-001 is currently […]
27 July 2022
Vaxxas patch worked for all Covid strains
A protein-based vaccine patch has proved effective against all major variants of Covid when given to mice, say researchers.  A protein-based vaccine patch has proved effective against all major variants of Covid when given to mice, say researchers. Vaxxas is an Australian biotechnology company which is developing patch dispensers for different diseases. Vaxxas CEO David […]
9 June 2022
Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Promising ‘dark matter’ cancer therapy has clinical trials in sight Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in cancer, is progressing towards clinical trials following a promising initial development phase and securing key appointments to its Scientific Advisory Board (SAB). Amaroq Therapeutics is pleased to announce […]
6 June 2022
Over $15m invested in world-leading cancer immunotherapy
University of Auckland spinout targeting new cancer treatment TamoRx, a biotech start-up recently spun out of the University of Auckland, has received NZ$15.25m investment to accelerate development of a new treatment for cancer. The company, founded by Dr Joanna Mathy and Professor Rod Dunbar from the university’s School of Biological Sciences, aims to develop a […]
31 May 2022
Vaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a possible alternative to […]
18 May 2022
Australian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials
OncoRes Medical’s imaging system may be a game-changer for breast cancer surgeons Australian medical device company OncoRes Medical today announces it has secured $12.5m to advance its innovative imaging system, to facilitate real-time tumour assessment to help surgeons more accurately identify and remove cancerous tissue such as breast cancer. The $9.5 million Series A2 funding […]
12 May 2022
ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. […]
12 May 2022
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
GLY-200 Well-Tolerated Across Doses Evaluated, Supporting Potential as First-in-class Treatment for Type 2 Diabetes and Related Metabolic and Chronic Conditions Initiation of Phase 2 Trial for GLY-200 in Patients with Type 2 Diabetes Anticipated in Mid-2022 Company’s Expertise in Gastroenterology, Metabolism, and Polymer Chemistry Further Strengthened by Recent Appointment of Mark Fineman, Ph.D., as Chief […]
6 May 2022
Aravax appoints Dr Brett Haumann to Board of Directors
Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors. Dr Haumann is a pharma veteran with leadership experience spanning […]
3 May 2022
Australian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions
Australian biotech company, Ankere Therapeutics (‘Ankere’), has launched with AU$10 million seed investment to develop new therapies which target inflammatory diseases, particularly those affecting the lung. The funding round was jointly led by IP Group and Brandon Capital, through Brandon BioCatalyst, and will support the company through its pre-clinical development and into clinical trials. Ankere […]
18 April 2022
Parkinson’s patients benefit from revolutionary watch on the NHS to manage care at home
Patients with Parkinson’s disease are being given life-changing smart watches that allow doctors to remotely assess their condition in a pioneering project to revolutionise NHS care. The cutting-edge gadget containing sensors, known as a Parkinson’s Kinetigraph (PKG), is worn around the clock for six days to monitor patients’ movements at home. The information it collects […]
12 April 2022
Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022
Human ex vivo data demonstrate the promise of Pathios’ ‘Macrophage Conditioning’ approach in reversing the immunosuppressive polarization of macrophages brought about by an acidic microenvironment Preclinical study results show the ability of GPR65 inhibition to inhibit tumor growth and increase infiltration of key effector cell populations Pathios Therapeutics Limited (“Pathios”), a biotech company focused on […]
4 April 2022
Boosting product confidence of a world-leading RNA therapeutics start-up
CSIRO’s Transformational Bioinformatics group validates the importance of long non-coding RNAs (lncRNAs) as novel cancer therapeutics targets. The Client  Amaroq Therapeutics is a New Zealand-based biotechnology company targeting long non-coding RNAs for next generation cancer therapies. The company is spun out of research from the University of Otago in Dunedin, New Zealand, and is funded […]
24 March 2022
Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches
Vaxxas to complete Phase 1 clinical studies in 2022 with the world’s first needle-free COVID-19 vaccine (HexaPro) to be delivered using Company’s proprietary microarray patch (HD-MAP) technology HexaPro is a second-generation SARS-CoV-2 spike protein that is similar to the spikes used in all COVID-19 vaccines on the U.S. market, but modified to be more stable […]
16 March 2022
First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray
ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections  ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of […]
4 March 2022
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
Phase 2 study of PVX108 to commence in United States and Australia Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, today announces that it has […]
23 February 2022
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals with COPD. ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory […]
18 February 2022
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 […]
17 January 2022
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to substantially increase efficacy and improve adherence to treatment, while minimising side effects George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announced that its proprietary […]
30 November 2021
Q-Sera enters exclusive agreement with Terumo Corporation for RAPClot™ rapid serum blood collection tube technology in Japan
Q-Sera Pty Ltd, an Australian venture-backed company, today announced a partnership with Terumo Corporation, the leading Japanese medical device company, which will see its patent protected RAPClot™ rapid serum tube technology manufactured and used in Japan. RAPClot™ serum tubes (evacuated blood collection tubes) produce high quality serum in less than five minutes, reducing the turnaround […]
24 November 2021
Silicon Valley pacemaker hopes to capture Aussie hearts with ASX float
Silicon Valley pacemaker startup EBR Systems expects Australia’s strong research focus on heart disease will be a fertile environment to develop the products it hopes will solve one of the world’s biggest global health problems. EBR, which is working on a new kind of “leadless” pacemaker system called WISE, listed on the ASX on Wednesday […]
19 November 2021
Hard WA border a boon for life sciences sector
WA’s tough border stance might make it difficult to find employees in many industries but for the State’s burgeoning life sciences sector, it’s had the opposite effect. Several companies in that space are reporting a “brain gain” as opposed to the much-feared “brain drain”, with new and developed talent returning to Perth before or during […]
28 September 2021
First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials
— ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that […]
16 September 2021
Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform
Financing led by Arboretum Ventures. Managing Partner Nicole J. Walker to join Allay Therapeutics Board of Directors ATX-101 to advance to Phase 2b development in total knee replacement surgeries in 2021 Financing will also support broader development of ATX platform for ultra-sustained pain relief Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to […]
15 September 2021
Hope offered to Australians suffering from a rare incurable fibrotic autoimmune disease, as clinical trials on new treatment commence
Melbourne biotech company, Certa Therapeutics, seeks patients with Diffuse Systemic Scleroderma, a debilitating chronic autoimmune disease, to participate in clinical trials in Melbourne and Adelaide Melbourne man, who received diagnosis on birthday, says Scleroderma is a ‘relentless beast that never lets you go’, that pushed him into an early retirement, but new trials and research […]
7 September 2021
Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board
Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland Dysfunction (MGD) and related eye diseases, today announced the appointment of Steven M. Altschuler, M.D., as chair of its board of directors. Dr. Altschuler brings over 20 years of experience building, scaling and leading world-class healthcare and biotechnology companies. He currently serves as […]
3 August 2021
Adelaide Type 2 Diabetes researchers zero in on an ‘operation in a pill’
Adelaide researchers are recruiting volunteers to test “an operation in a pill” — a tablet to put type 2 diabetes into remission. Described as the Holy Grail of diabetes research, the pill will be tested on 64 healthy adult volunteers at CMAX in the CBD. The program is now seeking volunteers — who do not […]
3 August 2021
Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment
Positive preclinical data suggests that Glyscend’s unique pill, mimicking gastric bypass surgery, will prove effective in treating type 2 diabetes An orally administered type 2 diabetes (T2D) therapy, which could mirror the astonishing effect of gastric bypass surgery in improving sugar control in diabetes patients, will commence recruitment for a Phase I clinical trial in […]
14 July 2021
Promising Australian COVID-19 preventative nasal spray commences Sydney Phase I clinical trial, seeks participants
First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including COVID-19, influenza and the common cold, seeks participants for first in-human safety trial in Sydney Australian biotech, ENA Respiratory, recently secured AU$32 million investment to clinically develop its therapy, INNA-051 INNA-051 reduced COVID-19 replication by up to 96 percent in gold-standard, peer-reviewed, […]
12 July 2021
George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director
George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director. Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader. Prior to joining the Board of […]
8 July 2021
Brandon Capital leads $14m investment to develop new cancer drug
A new spinout from the University of Otago has secured $14 million in backing to help develop a new kind of targeted cancer drug in the emerging field of RNA therapy. The Amaroq Therapeutics team, led by chief scientific officer and founder Dr Sarah Diermeier, are pioneers in exploring the use of long non-coding RNA […]
8 July 2021
$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments
Amaroq Therapeutics, a new biotech start-up spun out of the University of Otago, with one of the world’s most advanced programs in next-generation RNA therapy to target cancer has secured NZ$14m investment to accelerate development. The study of long non-coding RNAs (lncRNAs), often referred to as “dark matter” of the genome, are molecules naturally present […]
1 July 2021
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension
Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes George Medicines, a late-stage drug […]
28 June 2021
Brandon Capital, Uniseed back cancer biotech start-up in $10m funding
A Melbourne-based start-up spun out of the Peter MacCallum Cancer Centre has raised $10 million for the further development of its novel cancer immunotherapy that targets solid tumours such as breast and pancreatic cancers. The Brandon Capital Partners-managed Medical Research Commercialisation Fund led the investment into biotech Currus Biologics, along with university commercialisation fund Uniseed, The fresh […]
28 June 2021
$10m invested into start-up developing new treatments targeting the use of CAR-T cell therapies against solid tumours
Cancer biotech start-up, Currus Biologics, is utilising its proprietary BEAT technology as a combination therapy with CAR-T cells targeting the treatment of solid tumours $10 million Series A investment received from leading life science Venture Capital investors Brandon Capital-managed Medical Research Commercialisation Fund (MRCF) and Uniseed Currus Biologics, a Melbourne-based cancer biotech start-up, has completed […]
22 June 2021
Ena Respiratory raises $24M to trial COVID-19 nasal spray
Ena Respiratory has raised up to $32 million Australian dollars ($24 million) to fund clinical development of a nasal spray designed to prevent COVID-19. The product, INNA-051, delivers a TLR2/6 agonist to upregulate innate immune responses in airway epithelial cells and thereby help suppress the coronavirus. While vaccines are bringing protection against COVID-19 to the masses, […]
21 June 2021
Forrest backs nasal spray play in fight against COVID-19
Andrew “Twiggy” Forrest’s Minderoo Foundation is partly financing a new $32 million funding round for a nasal spray start-up that says it can help the fight against COVID-19. Ena Respiratory also secured backing from biotech investors Brandon Capital and Uniseed for the round. The capital will help develop its INNA-051 spray, which is due to start human studies […]
16 June 2021
Australian spinout eyes the clinic with a prophylactic nasal spray for Covid-19
Whether patients are immunocompromised or just don’t like needles, one fledgling Australian biotech says it has an alternative to Covid-19 vaccines that doesn’t involve a jab in the arm — and on Tuesday, it pulled in a fresh round of funding to take it into the clinic. ENA Respiratory, which spun out of ENA Therapeutics […]
15 June 2021
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise
Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D. to Board of Directors ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention […]
3 June 2021
George Medicines appoints Stefan König as Chief Executive Officer
Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for non-communicable diseases US FDA grants IND authorization to commence Phase III trials with triple combination candidate for the treatment of hypertension Chief Business Officer, Karl Roberts, appointed to new role of Chief Operating Officer George Medicines, a late-stage drug […]
3 June 2021
Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal model Complete protection from COVID-19 disease by a single dose skin patch delivery using Vaxxas’ HD-MAP was demonstrated in a lethal challenge of the SARS-COV-2 virus in an animal model Serum antibody levels […]
14 May 2021
Adelaide’s BioMed City is attracting strong clinical trial interest as its critical mass continues to grow
There has been a 50 per cent increase in clinical trials in Adelaide as a result of the state’s safe-haven status throughout the COVID-19 pandemic, the general manager of Adelaide BioMed City says. Yvette van Eenennaam, who is also chair of the SA Genomics Centre, said the $3.8 billion precinct at the western end of […]
13 May 2021
Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform
First clinical data to demonstrate non-opioid pain relief lasting two weeks after one administration, where current post-surgical pain products are effective for a maximum of three days Significant reductions in pain and opioid usage relative to standard of care – Clinical candidate for support of total knee replacement surgery, ATX-101, to move into Phase 2b […]
3 May 2021
FDA fast-tracks Australian breast cancer technology
An Australian imaging device about the size of an electric toothbrush that could save breast cancer patients from going under the knife multiple times has been fast-tracked by the US Food and Drug Administration. West Australian medical technology company OncoRes is ­behind the ­device that uses new technology to make real-time ­tumour assessments and help […]
3 May 2021
FDA grants Australian breast cancer innovation ‘Breakthrough Device Designation’ status
OncoRes Medical has received ‘Breakthrough Device Designation’ from the U.S. Food and Drug Administration (FDA) to expedite development of its Quantitative Micro-Elastography (QME) Imaging System. This innovative technology is designed to facilitate real-time tumour assessment to help surgeons more accurately identify and remove cancerous tissue—an approach that could substantially improve outcomes in breast-conserving surgery (BCS) […]
22 April 2021
Strong quarter for Osprey with continued growth in units and revenue
Osprey Medical Inc. (ASX:OSP) (Osprey or the Company) today released its Appendix 4C – Quarterly Cash Flow Report for the period ending 31 March 2021 (1Q 2021 or the Quarter). Key Highlights • Group: COVID recovery continues with worldwide units sold up 14% and revenue up 21% on previous quarter • US: Lean expansion with […]
15 April 2021
World’s First Leadless Left Bundle Branch Area Pacing Implant Utilizing EBR Systems’ WiSE CRT System
Prof Pascal Defaye of CHU de Grenoble-Alpes performed world first Leadless LBBAP implant. EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that Professor Pascal Defaye, Head of Rhythmology and Cardiac Stimulation Unit, CHU de Grenoble-Alpes, France, performed the world’s first successful Leadless Left Bundle Branch Area […]
9 April 2021
VC Land Podcast: Shining a light on biotech with Brandon Capital
The VC Land Podcast connects you with some of the leading players in Australia’s growing venture capital (VC) market. Hosted by news media and PR veteran, CEO of Mojomedia.com.au, Justin Kelly, we chat to leading VCs on how to get started, what it takes to build a successful business, how to overcome challenges, and advice for […]
8 March 2021
Azura heads for final studies for world-first dry eye treatment
Brandon Capital-backed biotech start-up Azura Opthalmics has made a big leap towards creating the world’s first treatment for a type of dry eye disease, publishing promising phase two clinical trial results last week. Most of the treatments available for dry eye, such as artificial teardrops, moisten the surface of the eye. But for 85 per […]
4 March 2021
Promising new potential treatment for leading cause of Dry Eye Disease a step closer as Azura Ophthalmics announces positive results in Phase 2 Program
Azura Ophthalmics moves into registration studies following positive Phase 2 Program results which could see its treatment for Meibomian gland disfunction – the leading cause of Dry Eye Disease – complete its first registration study by early next year Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD), today announces […]
22 January 2021
OncoRes Medical receives $150,000 funding boost from Western Australian Government
Innovation and ICT Minister Dave Kelly today announced the McGowan Government will invest $150,000 in funding from the New Industries Fund into Western Australian-based medical device start-up OncoRes Medical to enhance R&D capability and create local jobs at their Nedlands-based facility. OncoRes Medical CEO, Dr Katharine Giles, said the funding will support OncoRes Medical’s continued […]
18 December 2020
Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals
Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the nose and throat by up to 96%; also found to be effective against rhinovirus (common cold), the […]
22 November 2020
Nasal spray which could fight Covid and other respiratory infections gets funding
A nasal spray with the potential to fight Covid-19 and other respiratory viral infections will be tested in the hope of manufacturing it in Australia. The INNA-051 nasal treatment, developed by the Australian biotech company Ena Respiratory, targets the primary site of most respiratory infections, including Covid, and activates immune defence mechanisms in the respiratory […]
17 November 2020
New investments for drug research
Brandon Capital, Sofinnova Partners invest $8.2 m in new UK start-up seeking novel cancer blocker. The Medical Research Commercialisation Fund and European venture capital firm, Sofinnova Partners, have co-led an initial investment of $8.2 million (£4.5 million) into Myricx Pharma, a new drug discovery company focused on developing novel treatments for cancer. The UK-based Myricx […]
16 November 2020
Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M (AU$8.2M) from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class […]
6 November 2020
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire […]
1 November 2020
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, announced today the appointment of Thomas Ulmer to the Board of Directors. Mr. Ulmer was previously the Chief Financial Officer of Immatics N.V., a NASDAQ-listed biopharmaceutical company and brings nearly two decades of experience serving in […]
29 October 2020
OncoRes Medical wins IGNITE Madness 2020
Perth-based medtech company, OncoRes Medical, has taken out the IGNITE Madness pitch competition in Houston, Texas, USA. In addition to the US$10,000 first prize, OncoRes Medical was awarded the prestigious Texas Medical Centre Ventures investment prize which is valued in excess of US$100,00. IGNITE is a newly organized non-profit organization comprised of a network of […]
26 October 2020
Eyeing pandemic’s silver lining for drug trials
The coronavirus pandemic has battered the smooth running of clinical trials for new drugs worldwide, but Australia has managed to pull through in a comparatively strong position, according to a biotechnology outfit researching an eye treatment. “Because Australia and New Zealand had done such a great job, with respect to managing the current rates of […]
23 October 2020
Azura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Medical Research Commercialisation Fund (MRCF) in raise for registration study to treat Meibomian gland dysfunction, the leading cause of Dry Eye Disease Meibomian gland dysfunction affects more than 30 million adults in the United States alone – registration studies used to seek potential regulatory approval with the FDA Financing also will support development of pipeline […]
5 October 2020
Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Needle-free Vaxxas HD-MAP patch offers potential platform to dramatically improve vaccination in pandemic response by producing more patient-doses from limited quantities of vaccine, enabling rapid vaccine distribution without refrigeration, and creating a novel option for self-administration. Initial BARDA funding focuses on clinical demonstration using pandemic influenza vaccine; Vaxxas investigating opportunities to improve performance of other […]
28 September 2020
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat, in a gold-standard animal study Reduced COVID-19 replication by up to 96%, study performed by Public Health England […]
28 September 2020
Nasal spray cuts COVID-19 growth, study shows
It is unclear yet the length of protection a vaccine will provide. If it only lasted a few months the nasal spray would add another level of protection. A novel nasal treatment developed to boost the human immune system to fight common colds and flu has proved successful in reducing COVID-19 viral growth in a […]
3 September 2020
Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions
Federal Governments Medical Research Future Fund provides grant to biotech company, Cincera Therapeutics Cincera Therapeutics Pty Ltd, a biotech company with operations in Adelaide and Melbourne, has been granted $1 million by the Biomedical Translation Bridge (BTB) Program. The funding will progress its research in developing a drug to treat severe and life-threatening obesity-related health […]
30 July 2020
GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)
GE Healthcare and Osprey Medical Inc. (ASX:OSP) (Osprey) today announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey. Osprey’s DyeVert™ contrast minimization devices, complemented by GE Healthcare’s range of iodinated x-ray contrast media, offer healthcare professionals a technology platform to […]
22 July 2020
OncoRes Medical awarded prestigious research funding
Perth-based medtech company, OncoRes Medical, has been awarded $1 million funding as part of the Australian Government’s Medical Research Future Fund BioMedTech Horizons program, operated by MTPConnect. The grant will help to fund the development of a second-generation intraoperative imaging device, designed to reduce repeat operations for women with breast cancer. OncoRes Medical, together with […]
12 June 2020
Innovative type two diabetes treatment scores $29m
An early stage non-invasive treatment for type two diabetes is set to begin human trials in Adelaide in late 2020, thanks to a $29 million cash injection from Brandon Capital’s Medical Research Commercialisation Fund and US fund Santé Ventures. The treatment is being developed by US company Glyscend Therapeutics. It is the result of a […]
12 June 2020
$29M investment to develop new treatment for type 2 diabetes
An orally administered treatment for type 2 diabetes (T2D), which mirrors the astonishing effect of gastric bypass surgery in improving sugar control in diabetes patients, has received a Series A investment of AU$29m. The funding round for biopharmaceutical company, Glyscend Therapeutics, was led by Brandon Capital’s Medical Research Commercialisation Fund (MRCF) and US healthcare investor, […]
29 May 2020
Vaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Brisbane, Queensland, Australia Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ USA, has exercised its option to utilize Vaxxas’ proprietary High Density Microarray Patch (HD‐MAP) platform for a vaccine candidate. MSD also retains an option to license the HD‐MAP technology for […]
28 May 2020
Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)
Needle‐free Vaxxas HD‐MAP can enhance routine vaccination with potential to revolutionize vaccination in pandemic response; produce more patient‐doses from limited quantities of vaccine, distribution without refrigeration, and potential for self‐administration. Collaboration lays engineering groundwork for capital expenditure investments of up to $25 million over the next 3 years. Harro Höfliger and Vaxxas will develop world’s […]
18 March 2020
Vaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication in the journal PLoS Medicine of groundbreaking clinical research indicating the broad immunological and commercial potential of Vaxxas’ novel high-density microarray patch (HD-MAP). Using influenza vaccine, the clinical study of Vaxxas’ HD-MAP demonstrated significantly enhanced immune response compared to vaccination by needle/syringe. This is […]
18 March 2020
Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination
Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that it has received a US$5 million [AU$7.5 million] grant to conduct initial human clinical studies using Vaxxas’ High Density Microneedle Array Patch (HD-MAP) for measles and rubella vaccination. This funding is provided by the Bill & Melinda Gates Foundation and builds on an […]
10 March 2020
Multi-million-dollar mission to tackle major global health challenges
The George Institute for Global Health today announced that $53 million from three Australian investors will now support the commercialisation of its world-leading research to address some of the biggest health challenges of our time. The investments are set to fast-track the growth of George Health Enterprises, the Institute’s commercial arm, and George Medicines, its […]
18 December 2019
Canaan backs Pathios’ search for small molecule drugs that hit ‘orphan’ GCPR
As fruitful as G protein-coupled receptors have proved for modern medicine — by common estimates, more than 30% of FDA-approved drugs target this class of proteins — there are still dozens of “orphan” GPCRs whose endogenous ligands are poorly understood. One of them is GPR65, a pH sensing receptor that British biotech Pathios believes plays […]
26 November 2019
In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx
At first glance, Darren Kelly doesn’t seem to sleep. He’s the CEO of not one but two fibrosis-related biotechs, an entrepreneur in residence at Brandon Capital, Australia’s largest life sciences-focused VC firm, a director at the Centre for Eye Research Australia and—to top it all off—the associate dean of innovation and enterprise at the University […]
23 October 2019
QUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats
Melbourne biotechnology company QUE Oncology has announced that the Royal North Shore Hospital is actively seeking patients for a clinical study, which will see its novel non-hormonal therapy tested on women with breast cancer to prevent debilitating hot flushes and night sweats. Breast cancer survivors are routinely prescribed drugs which reduce or block the action […]
26 September 2019
$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease
A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd. The company was set-up to develop and commercialise the research outputs of a long-running programme originating from the University of Melbourne working in collaboration with CSL. […]
10 September 2019
FDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System
EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the WiSE CRT System for the treatment of heart failure. The FDA created this designation and its associated program in 2017 for certain devices […]
28 August 2019
Perth tech joint-winner in global finals for international start-up competition
Perth medical device company, OncoRes Medical, has been announced as one of three ‘Entrepreneurs of the Year’ at the global finals of an internationally-recognised start-up event, following a pitch overnight to an international audience including the Duke of York, Prince Andrew. OncoRes, which is developing an imaging tool to improve the outcome of breast cancer […]
27 August 2019
EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO
EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of its pivotal SOLVE CRT clinical trial and to prepare for commercialization of the WiSE Cardiac Resynchronization Therapy (CRT) System. This financing was led by Australian private equity firms Brandon […]
20 August 2019
Q-Sera’s innovative blood clotting technology granted patent in US
Medical device company Q-Sera Pty Ltd today announces that it has received a Notice of Allowance from the United States Patent & Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes. The Q-Sera technology is based on lead active RAPClotTMwhich has been shown to rapidly produce […]
1 August 2019
QUE Oncology launches Phase II trials in New Zealand
Australian biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flushes and night sweats, tested across at least three sites in New Zealand. QUE Oncology is developing drugs for large unmet medical needs and has already advanced […]
29 July 2019
QUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors
QUE Oncology, a clinical-stage biotechnology companydeveloping a novel treatment for breast cancer patients suffering debilitating hot flashes, today announces the appointment of two highly-regarded life science executives to its Board of Directors. Dr. Julie Cherrington and Elizabeth Cermak have been appointed to the board, each bringing decades of experience from both large pharmaceutical and start-up […]
23 July 2019
PolyActiva completes recruitment in key Phase I glaucoma implant safety study.
PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma. PolyActiva’s implant has the potential to revolutionise the treatment for millions of glaucoma patients. Current glaucoma […]
22 May 2019
Morphoseq™ at ‘Sequencing, Finishing and Analysis in the Future’ meeting, USA
Longas Technology Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis in the Future’meeting, May 21 – 23, Santa Fe, NM, USA, that enables long read sequencing on short read NGS platforms. Developed over the […]
16 May 2019
Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology
Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its Morphoseq™ technology and announcing the appointment to CEO of Nick McCooke, who built and led the team at Solexa that pioneered NGS prior to the company being acquired by Illumina. Morphoseq is a disruptive technology […]
2 April 2019
QUE Oncology launches Phase II trials in the United States
Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States. QUE Oncology is developing drugs for large unmet medical needs and has already advanced […]
15 March 2019
MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis
The Medical Research Commercialisation Fund’s Biomedical Translation Fund (MRCF BTF) today announced the launch of a new biotech company, Respirion Pharmaceuticals Pty Ltd (Respirion). Respirion is developing a novel antibiotic therapy for the treatment of the life-threatening disease, Cystic Fibrosis (CF), combining an inhaled version of an approved drug that is normally used to capture […]
25 February 2019
Aravax reveals positive Phase I trial results at world-leading allergy conference
Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advantages in safety and practicality, has presented its clinical trial results at one of the world’s most prominent allergy conferences today. Melbourne-based Aravax today announced positive results from the Phase I trial of its peanut allergy therapy, at […]
31 January 2019
Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis
Okogen, a biotech company developing ophthalmic therapeutics, today announces the launch of Phase II trials which will see its lead therapy trialled on patients with conjunctivitis across Australia. The Phase II clinical trial (RUBY) will evaluate the safety and efficacy of Okogen’s lead candidate, OKG-0301, in the treatment of acute adenoviral conjunctivitis (commonly known as […]
3 December 2018
Perth tech takes out Australian start-up competition to join international finals
Perth medical device company, OncoRes Medical, has won top honours at an internationally-recognised start-up event, which will see the company pitch to an international audience including the Duke of York, Prince Andrew. OncoRes, which is developing an imaging tool to improve the outcome of breast cancer surgery, beat off stiff competition to win the Australian […]
2 October 2018
QUE Oncology launches Phase II trials
Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flushes and night sweats, tested at six sites across Australia. QUE Oncology is developing drugs for large unmet medical needs and has already advanced clinical development […]
31 August 2018
PolyActiva commences first Phase I clinical trial with potential to improve lives of millions
PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is safe and well tolerated. PolyActiva has used its proprietary polymer prodrug technology to develop ocular implants that, when placed in the eye, provide sustained treatment over a six-month period, […]
14 August 2018
Paragen Bio launches in northern Queensland with $6 million investment
Brandon Capital’s Medical Research Commercialisation Fund (MRCF), AbbVie Ventures, and OneVentures today announce an AU$6 million investment into new biotech company, Paragen Bio Pty Ltd. This is the first biotech startup from James Cook University (JCU) and is one of just a handful of biotech companies in Northern Queensland. Paragen Bio is focused on treating […]
3 July 2018
Azura Ophthalmics receives Series B funding to create treatment for major cause of Dry Eye Disease
Azura Ophthalmics has received US$16 million in Series B funding to develop treatments for Meibomian Gland Dysfunction (MGD) – the number one cause of Dry Eye Disease. The funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF), TPG Biotech, OrbiMed and Ganot Capital, will allow the Israeli-Australian company to move into its next clinical stage […]
4 June 2018
MRCF announces largest investment to date by Biotechnology Translation Fund
The Medical Research Commercialisation Fund (MRCF) today announce a significant AU$25 million investment into late-stage biomedical company, Certa Therapeutics. This is the largest investment to date from the Government’s Biotechnology Translation Fund (BTF), with $22M coming from the MRCF and over $3M from Uniseed. Certa Therapeutics is focused on the emerging field of medical science […]
4 June 2018
Brandon Capital’s MRCF announces largest investment by Biotechnology Translation Fund
The Medical Research Commercialisation Fund (MRCF) today announce a significant AU$25 million investment into late-stage biomedical company, Certa Therapeutics. This is the largest investment to date from the Government’s Biotechnology Translation Fund (BTF), with $22M coming from the MRCF and over $3M from Uniseed. Certa Therapeutics is focused on the emerging field of medical science […]
28 February 2018
Conjunctivitis treatment gets $13m from Brandon Capital for local trial
Australians with viral conjunctivitis will be the first to try drops that hope to clear up the eye infection and reduce its fortnight-long infectious period, after an opthalmic drug developer was lured from San Diego to Sydney by $13 million from a local biotech venture capital manager. The Sydney Eye Hospital will host the first […]
28 February 2018
Okogen receives $13 Million Series A Funding for trials to treat the leading cause of eye infections
Okogen, a San Diego developer of ophthalmic anti-infective drugs, announces AU$13 million in Series A Funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance its viral conjunctivitis treatment. The investment will go towards the ongoing development of Okogen’s lead candidate, OKG-0301, an ophthalmic formulation of ranpirnase, a potent ribonuclease with established broad-spectrum antiviral […]
28 February 2018
MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia
Okogen, a San Diego developer of ophthalmic anti-infective drugs, announces AU$13 million in Series A Funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance its viral conjunctivitis treatment. The MRCF has a trainee/secondee program, whereby Member Institutes or allied public sector initiatives can nominate staff members to work within the Investment Manager for […]
19 February 2018
Australian biotech company launched with AU$7m investment to develop therapies for treating obesity
Cincera Therapeutics Pty Ltd (“Cincera”) has launched with an AU$7 million venture capital commitment from the Medical Research Commercialisation Fund (MRCF). The Company has been founded to develop new therapies to target conditions relating to an unhealthy Western diet, including serious and highly prevalent diseases associated with obesity. The company will initially focus on treatments […]
9 February 2018
University of Sydney spin-off Elastagen sold for $120m to Botox maker
Ridding the world of stretch marks and acne scars is on track to become Professor Anthony Weiss’s legacy, after the skin repair treatment developed at his University of Sydney biochemistry laboratory in the 1990s was sold for $120 million to the multinational that makes Botox. Professor Weiss’s breakthrough was a process to manufacture tropoelastin, a […]
2 February 2018
Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio
Elastagen Pty Ltd, a clinical stage company developing medical device products based on recombinant tropoelastin, today announced that it has entered into a definitive agreement under which Allergan plc, a leading global biopharmaceutical company, has agreed to acquire Elastagen for an upfront payment of US$95M plus contingent, commercial payments.” Elastagen’s revolutionary technology is based on […]
13 December 2017
New Zealand biomedical discovery set to revolutionise the global pain relief drug market
Commercialisation Fund (MRCF) today announces an investment of NZD$8 million in Series A funding for Kea Therapeutics Ltd., an early stage pharmaceutical company which is developing a new drug for the relief of severe pain. Kea Therapeutics is a spin-out of the Auckland Cancer Society Research Centre (ACSRC) and Faculty of Medical and Health Sciences […]
14 November 2017
Venture capitalist Mark Carnegie leads $65m wireless pacemaker funding
Venture capitalist Mark Carnegie was alerted years ago by a science adviser to a Californian developer of a wireless heart pacemaker that could save the lives of some patients, but he baulked at the terms. Every month the adviser would call Mr Carnegie and say, “I have got another CRT patient who is going to […]
17 October 2017
Azura Opthalmics raises $20m from Brandon Capital, others for dry eye cure
One of the year’s biggest investments in an Australian biotech is for one of medicine’s great unsolved problems: dry eye disease. Sydney-based Azura Opthalmics has raised $US16 million ($20.3 million) to advance clinical trials of a treatment for meibomian gland dysfunction (MGD), the culprit in more than 70 per cent of dry eye cases. “Having […]
5 June 2017
UQ breast cancer drug maker QUE Oncology raises $21.5m from Medical Research Commercialisation Fund
The Medical Research Commercialisation fund has led a $21.5 million raise into anti-cancer therapies company QUE Oncology, funding the development of a drug that stops breast cancer survivors suffering hot flushes during endocrine treatments. The company was founded in 2013 as a joint venture established by Emory University in Atlanta and the University of Queensland’s […]
29 May 2017
Brandon Capital on board as Parkinson’s smartwatch firm Global Kinetics seeks $30 million
Emerging Australian medtech success story Global Kinetics is raising $20-30 million to keep commercialising its smartwatch-style Parkinson’s treatment device. The company is also working on an expansion into telehealth in partnership with French hospitals and developing an app to give Parkinson’s patients more control over their own treatment. The latest capital raise follows a $14.8 million […]
23 May 2017
Researchers backed with $6.3 million in hunt for a cure to the common cold
A cure for the sniffles has long eluded science, but research teams in Newcastle and Melbourne have just received $6.3 million for trials of a molecule they hope can block the virus that causes three-quarters of all colds. The culprit that the scientists from Hunter Medical Research Institute (HMRI) and University of Melbourne are after is rhinovirus, […]
16 May 2017
457 visa crackdown derails drug to cure blindness
Things looked great for Xianzhong Lau a month ago. The 30-year-old Singaporean had completed a PhD in translational biology and snared a job as a project leader with a company founded by one of Australia’s top life sciences entrepreneurs, Darren Kelly. All he needed was the 457 visa that he had already applied for to […]
29 June 2015
Novartis takes a pain med in $700M buyout deal for Spinifex
A little more than a year ago, Melbourne, Australia-based Spinifex decided to take part of a $45 million round to set up an office in Stamford, CT, with the clear intention of putting its mid-stage pain drug in a better position on Big Pharma’s food chain. And today that strategy paid off handsomely with a […]

Contact Us

Melbourne

Level 9, 31 Queen Street

Melbourne VIC 3000

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

Sydney

Suite 2.05, 1 York Street

Sydney NSW 2000

Phone +61 2 8227 7080

Email: info@brandoncapital.com.au

San Francisco

Brandon Capital LLC

1 Letterman Ave, Suite C3-330

San Francisco, CA 94129

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

London

The Gridiron Building, 1 Pancras Square

Kings Cross, London N1C 4AG

United Kingdom

Email: info@brandoncapital.com.au

For media inquiries, contact

Kirrily Davis

kdavis@brandoncapital.com.au

+61 401 220 228


© Copyright 2024 Brandon Capital Partners

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.